CI Financial Advances Mubadala Arrangement with Holdco Option
CI Financial Corp. has received an interim court order for its proposed plan of arrangement with Mubadala Capital, allowing the acquisition of its shares for $32.00 per share, excluding those of senior management who opt for equity rollover agreements.
Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...
Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...
Healthcare-focused SaaS firm Innovaccer Inc. has secured $275 million in funding from investors including B Capital Group and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback